BioStock: BioInvent presents additional positive study data

Bioinvent, who on January 3rd will be moved up to Nasdaq Stockholm’s Mid Cap segment, has presented positive early data from the ongoing study where the drug candidate BI-1206 is combined with Keytruda for the treatment of patients with solid tumours. One of the most notable observations was that one of the participating patients clearly improved, was able to stop all pain medication and could go back to working. BioStock contacted CEO Martin Welschof for a comment.

Read the full interview with Martin Welschof at biostock.se:

https://www.biostock.se/en/2021/12/bioinvent-presents-additional-positive-study-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/